Home › Autosomal Dominant Polycystic Kidney › NCT07745920

Managing Depressive Symptoms in ADPKD

A Pilot Study for Managing Depressive Symptoms in Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Who can join

Ages 18 to 70 · All sexes

Inclusion criteria:

* Confirmed clinical diagnosis of ADPKD using Pei-Ravine criteria
* Pre-End Stage Kidney Disease, with Stage 1-5 CKD (eGFR \>10 ml/min/1.73m2, with no anticipated dialysis or transplant within 12 months)
* Clinical or self-diagnosis of depression
* English-language fluency

Exclusion criteria:

* Suicidal ideation/unstable mental illness of any kind
* Lack of access/ability to use internet-based programs
* eGFR \<10 ml/min/1.73m2
* Anticipated dialysis or transplant within 6 months
* Prior chronic dialysis
* Prior organ (liver or kidney) transplant
* Lack of English language fluency
* Significant cognitive impairment (Mini Mental Status Exam (MMSE))

About the study

The purpose of this research is to evaluate the feasibility and effectiveness of Digital Neurotherapy (DNT) or Capacity Coaching (CC) for managing symptoms of depression and self reported pain in Autosomal Dominant Polycystic Kidney Disease (ADPKD) compared to education alone.

What is being tested

• Mayo Clinic-Approved Education (behavioral)
• Digital Neuropathy (behavioral)
• Capacity Coaching (behavioral)

Sponsor: Mayo Clinic · Participants: 105 · Started: Jun 12, 2026

Contact the study team

• Ryan Helland, CCRP · Phone: 507-422-3998

Official record on ClinicalTrials.gov — NCT07745920

Locations in the U.S.

Conditions

• Autosomal Dominant Polycystic Kidney

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.